Virtu Financial LLC Makes New Investment in Tharimmune, Inc. (NASDAQ:THAR)

Virtu Financial LLC bought a new stake in Tharimmune, Inc. (NASDAQ:THAR) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 21,371 shares of the company’s stock, valued at approximately $44,000. Virtu Financial LLC owned approximately 1.11% of Tharimmune as of its most recent SEC filing.

Tharimmune Trading Down 5.9 %

Shares of Tharimmune stock opened at $1.28 on Wednesday. The company has a 50-day moving average of $1.69 and a two-hundred day moving average of $2.07. Tharimmune, Inc. has a 12-month low of $1.20 and a 12-month high of $7.46. The stock has a market cap of $2.48 million, a PE ratio of -0.13 and a beta of 1.28.

Tharimmune (NASDAQ:THAR) last released its quarterly earnings data on Tuesday, March 25th. The company reported ($2.02) EPS for the quarter.

Analysts Set New Price Targets

THAR has been the topic of a number of recent analyst reports. Rodman & Renshaw began coverage on Tharimmune in a report on Friday, December 6th. They set a “buy” rating and a $17.00 price objective on the stock. RODMAN&RENSHAW raised shares of Tharimmune to a “strong-buy” rating in a research note on Friday, December 6th.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).